Background Pricing drugs in the California Workers' Compensation System (CAWCS) has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. The objectives of this study are (1) to explore any trends in physician-dispensed drug prices; (2) to compare the proportion of drugs with and without a price and to determine the financial implications of repricing CAWCS physician-dispensed drugs with five alternative pricing benchmarks; and (3) to offer recommendations for the pricing benchmark to maximize pricing coverage and to remain budget neutral. Methods We evaluated physician-dispensed drugs at the transaction level, reimbursed in the CAWCS. Frequency, reimbursement rate, and total and average paid costs were reported. We matched each claim line in the CAWCS to the corresponding unit price of an alternative price benchmark including average wholesale price, wholesale acquisition cost, direct prices, national average drug acquisition cost, and Federal Upper Limit. Results Average wholesale price provided prices for 99.9% of physician-dispensed drug claims, while Medi-Cal, the current primary physician-dispensed drug benchmark provided prices for a lower percentage (92.7%) of claims. The CAWCS prices were equivalent to 49% of the average wholesale price, 95.5% of Medi-Cal, 126.7% of the wholesale acquisition cost, 266% of the Federal Upper Limit, 64.4% of direct prices, and 197% of national average drug acquisition cost-estimated prices. Conclusions The CAWCS current Medi-Cal pricing for physician-dispensed drugs is better than all alternatives in terms of price availability, transparency, and budget neutrality, but pricing availability may decrease over time as Medi-Cal moves to managed care. National average drug acquisition cost is the next best alternative, but it requires combinations of pricing benchmarks to maximize its price availability.
Introduction
The California Workers' Compensation System (CAWCS) is the largest workers' compensation system nationwide, covering 18 million employees in California in 2013, and also with the largest drug expenditure (US$300 million in 2015), including both drugs dispensed by physicians and in retail pharmacies [1] . Physician dispensing is allowed in most states but only in certain circumstances, with workers' compensation systems being the main payment sources for physician dispensing. The costs of physician-dispensed drugs (PDDs) within the CAWCS are 60-300% [2, 3] higher than the same drugs dispensed at a retail pharmacy [3] , owing to different payment regulations. This discrepancy has received considerable scrutiny.
In 2007, the CAWCS attempted to minimize the financial risk of physician dispensing by amending the physician drug reimbursement schedule to match the pharmacy rate. This changed the Official Medical Fee Schedule reimbursement rate for all drugs from 140% of the average wholesale price (AWP) to 100% of the California Medicaid (Medi-Cal) outpatient pharmacy fee schedule, largely eliminating the differential pricing resulting in such high costs of PDDs [4, 5] . By 2011, both the volume and amount paid for physiciandispensed repackaged drugs declined by 90% [6] .
Medi-Cal was selected as the new benchmark because it typically has generous drug coverage and also receives the largest rebates for medications as a result of a federal regulation requiring drug manufacturers to sign rebate agreements with the Centers for Medicare and Medicaid Services (CMS) or forego coverage of their drugs by state Medicaid programs [7] . After adopting the new Medi-Cal-based reimbursement system, overall drug spending by the CAWCS declined by 27% from 2004 to 2007, but then increased by 42% from 2007 to 2013. Reports on PDDs since 2011 has largely focused on the dispensing of compounded drugs and there has been no update on the total costs of non-compounded PDDs followed the increasing trends of overall drug spending. Medi-Cal has become increasingly more limited in the number of drugs with price provided, as more beneficiaries have moved to managed care plans whose drugs are not included on the Medi-Cal primary fee schedule price list used to price CAWCS fee schedule drugs. This presents a challenge of providing timely and accurate reimbursement because in the absence of a Medi-Cal drug price benchmark to determine the CAWCS price for PDDs, a financial liability loophole is created that may allow inflated prices over time [8, 9] .
The CAWCS suggests that the current Medi-Cal pricing benchmark is no longer adequate, with too many PDDs without a benchmark price (personal communication, CAWCS, Department of Industrial Relations, 2015) . The objectives of this study are three fold: (1) to explore any trends in PDD prices across 2011-2013; (2) to compare the proportion of CAWCS PDDs that have a price in each of five possible alternative pricing benchmarks and to determine the financial implications of repricing the CAWCS PDDs with each alternative pricing benchmark; and (3) to offer recommendations of the best pricing benchmark or combination of benchmarks for PDDs that maximizes pricing coverage and remains budget neutral.
Materials and Methods

Data Sources and Variables
Claims level data from the Workers' Compensation Information System were used to estimate total annual expenditure, number of claims, average expenditure per claim, and average expenditure per unit dispensed for PDDs. Dispensing transactions between 1 January, 2011 and 31 December, 2013 were obtained from the Division of Workers' Compensation [10, 11] . The study protocol was granted an exemption from the Institutional Review Board of the University of California, San Francisco because only unidentified claims data were used in the analysis.
Workers' Compensation Information System data were divided into four data subsets: physician-dispensed/administered drugs, compounded drugs, medical foods, and pharmacy-dispensed drugs. Physician dispensed drugs are drugs that are dispensed in-office, but not administered to the patient by the physician, while physician-administered drugs are those drugs that are administered in the physician's office (mostly injectable and intravenous drugs). Only the PDDs were analyzed in this study because physician-administered drugs are all priced using the average sales price within Medi-Cal, and other benchmarks do not have prices for physician-administered drugs. The analysis of the other data subsets is published elsewhere [12] . Workers' Compensation Information System claims included drug description, date of service, drug names brand/generic, 11-digit National Drug Code (NDC), billed amount, reimbursement total paid amount to physician, claim number, prescription service date, dispensing fee, claim status (e.g., denied, paid, modified paid, pending), and unit quantity dispensed. Quantity dispensed was coded by the smallest dispensable unit (tablets, capsules, milliliter for solutions, and grams for creams/ ointments) [11] . The NDC identifies the manufacturer, drug dispensed, strength of the drug, and the wholesale package size.
Several different pricing benchmarks were considered as alternatives for pricing CAWCS PDDs. Wholesale acquisition cost (WAC) is the unit price of a drug from the manufacturer to a wholesaler or a direct purchaser. Average wholesale price is the unit price of a drug when purchased at the wholesale level reported by the manufacturer and has been used for over 40 years as the major price benchmark for most drug reimbursement because of its easy availability [13] . Average wholesale prices are typically calculated by a fixed percent mark-up of WAC [14] . Direct price (DP) is a list price used for invoices between drug manufacturers and pharmacies or providers [15] . Criticisms of AWP and WAC are that they are subject to artificial inflation. Average wholesale price, WAC, and DP have been criticized for a lack of transparency and not being representative of the actual transactions after discounts and rebates [16] .
National average drug acquisition cost (NADAC) and the Federal Upper Limit (FUL) are determined and closely overseen by the CMS. National average drug acquisition cost was created by the CMS as a national price benchmark for outpatient drugs and NADAC prices are determined from a monthly random sample survey of community pharmacies in USA. The FUL is determined by the CMS only for generic drugs with multiple sources [17, 18] (Table 1) .
Monthly Medi-Cal unit price files were obtained from the publicly accessible California Department of Health Care Services website [19] . A different dataset including AWP, WAC, DP, FUL, and NADAC prices was obtained from the Medi-Span Drug Database, a Wolters Kluwer database available for licensing. Average wholesale price, DP, and WAC were obtained from Medi-Span's Comprehensive Price History Drug File, while NADAC and FUL were obtained from Medi-Span's Federal Government Pricing File [20] [21] [22] [23] . Only historic files with effective price dates of 31 December, 2013 or earlier were considered for analysis. The NDC, unit of quantity dispensed, and the date of service were used to match each fee schedule benchmark to CAWCS drugs for the repricing analysis. National average drug acquisition cost prices were not available in 2011, thus to estimate 2011 prices, we deflated NADAC prices from 2012 by the 2011 annual Consumer Price Index inflation rate for prescription drugs.
Data Analysis Plan
This is a retrospective descriptive analysis of CAWCS claims data. For the trend analysis, we evaluated PDD prescriptions at the transaction level, reimbursed in the CAWCS. Frequency, reimbursement rate, and total and average paid costs were reported annually from 2011 to 2013. We then matched each claim line in the CAWCS by the 11-digit NDC and date of prescription to the corresponding unit price of the same NDC of each alternative price benchmark to determine what percentage of the total NDC-based CAWCS claims had a corresponding NDC price for each pricing benchmark.
Using the CAWCS NDC-based claims that had NDC prices in each pricing benchmark, we repriced that set of 'matched' claims for each pricing benchmark. To estimate the CAWCS costs for each different pricing benchmark, the quantity dispensed for each claim was multiplied by the unit price for each NDC that had a price in each different pricing benchmark. We then compared the prices of each pricing benchmark with the current CAWCS prices. We report the trends in CAWCS PDD costs for 2011-2013, percentage of CAWCS claims that had NDC-based prices in both MediCal and each alternative pricing benchmarks, compare the costs of implementing alternative price benchmarks relative to the current pricing mechanism, and compare the financial impact of implementing alternative price benchmarks among drugs priced by multiple pricing systems. Recommendations are based on which benchmark has the most prices available, has the least impact on the budget, and is also perceived as transparent. 
Results
Trend Analysis
Between 2011 and 2013, there were 20,373,477 claims submitted to the CAWCS through the pharmacy fee schedule. Of these, 12,529,977 claims were for pharmaceutical products rather than for supplies or devices (including drugs that are pharmacy dispensed, physician dispensed, physician administered, and all compounded drugs and medical foods). Physician-dispensed drug claims accounted for 27.2% (3, 404, 678 ) of all pharmaceutical product claims. The number of PDD claims increased slightly over the 3 years from 1,095,751 claims in 2011, to 1,144,497 in 2012, to 1,164,430 in 2013, an increase of 6.3% (Table 2) .
Between 2011 and 2013, the total amount paid by the CAWCS was over US$242.3 million for PDDs. The total annual expenditures for PDDs increased from US$68. (Table 2) .
Analgesics accounted for most (33%) of the total claims across the years, with anti-inflammatory drugs the next most common (25%) of the total claims and gastrointestinal agents the third most common with 13.3% of total claims. Of the top six drug classes by number of claims, gastrointestinal agents accounted for the most costs (28.9%) of total paid amounts across all years, with analgesics and anti-inflammatory drugs accounting for 25% and 16% of the costs, respectively. The top six drugs accounted for 87% of total claims and 83% of total costs (Table 3) .
Repricing California Workers' Compensation System Drugs
Repricing California Workers' Compensation System National Drug Code Claims with Prices for Physician-Dispensed Drugs in each Alternative Pricing Benchmark
Several steps are necessary to determine the best alternative pricing benchmark for the payment of CAWCS PDDs based on our criteria of price availability, budget impact, and transparency. First, the proportion of the PDD NDCs that were billed to CAWCS (2011-2013) that also had a price available for each alternative pricing benchmark was determined. The CAWCS Medi-Cal fee schedule payments (2011-2013) were compared again with Medi-Cal prices. We found that Medi-Cal had prices available for 92.7% of total PDD NDC prescriptions (3, 156 ,139 claims out of 3,404,678). This price availability increased over the years from 90.5% in 2011 to 95.3% in 2013 [ Table 4 and (Table 4 and Table 7 of the ESM). Price comparisons by NDC were then made by repricing each unique sample pair where the current CAWCS MediCal-based fee schedule prices were also available for each alternative pricing benchmark. We then used this repricing to determine what discount or mark-up would be required for each pricing alternative to remain budget neutral for each (Table 4 and Table 7 of the ESM).
Repricing Analysis of California Workers' Compensation System Drugs that have no Prices for each Alternative Pricing Benchmark
To obtain an accurate assessment of the effect of adopting a new pricing benchmark to reprice the PDDs in the CAWCS, it is necessary to also examine the budget impact of those NDCs that have no price for each primary alternative pricing benchmark. The total annual payment for PDD claims that had no Medi-Cal prices was US$6.88 million in 2011, US$4.7 million in 2012, and US$2.29 million in 2013 ( Table 5 and Table 8 of the ESM). The amount paid by the CAWCS in comparison to different pricing benchmarks for those drugs that had no Medi-Cal price was 37.1% of AWP-estimated costs for drugs that have a unit price under the AWP fee schedule. For PDD claims that had no AWP, the CAWCS paid 19.8% of NADAC-estimated costs, 67.6% of WAC-estimated costs, and 340.4% of FUL-estimated costs ( Table 5 and Table 8 of the ESM).
Recommendations
Our recommendations are based primarily on finding a benchmark that has the largest proportion of available prices for drugs used by the CAWCS. In addition, we favor benchmarks whose source of prices is transparent and are promoted by other government-based pricing systems. Finally, we include in our recommendation a goal of either remaining budget neutral or cost saving. Although AWP has prices for the most (99.9%) drugs, its prices are not transparent. The CAWCS current Medi-Cal fee schedule has prices for the next largest percentage of PDDs than all other alternative pricing benchmarks, and also has transparent pricing and therefore should be at the top of our recommendations for a primary pricing system for CAWCS. However, although the Medi-Cal proportion of PDDs with prices increased annually during our study period, this proportion may be decreasing now as more Medi-Cal patients are being insured through managed care with drug payments excluded and therefore not providing Medi-Cal fee schedule prices [26] [27] [28] . Therefore, alternative primary pricing benchmarks are also analyzed in addition to Medi-Cal.
However, regardless of which pricing benchmark is chosen as the primary fee schedule, we demonstrate that a secondary pricing mechanism will be required to price all CAWCS drugs. Several combinations of pricing benchmarks are suggested that will both maximize price availability in both the primary and secondary pricing mechanisms and remain budget neutral or optimize CAWCS healthcare resource costs. In addition, attention is paid in our recommendation to the preferences being shown in Medicare to move away from AWP-based pricing, which is not transparent and has been subject to manipulation [26] [27] [28] . The frequency of utilization of benchmarks by other states is also considered in making our recommendations. Our recommendations for repricing and the challenges of each are outlined below (Table 6 ).
1. Keep primary payment using the Medi-Cal fee schedule but change the way drugs not covered by the primary Medi-Cal fee schedule are reimbursed; for example:
(a) For drugs not covered by the Medi-Cal fee schedule for PDDs and to remain budget neutral, the CAWCS would need to pay 37% of AWP (AWP-63%). However, because the lowest paying formula that we have seen is AWP-50%, and more commonly AWP-37%, then these payments could also be used. (b) FUL, which has prices for the second most PDDs that were not priced by Medi-Cal can also be considered for secondary payment in combination with AWP. For example, for PDDs without Medi-Cal prices, one could calculate payment as the lower of (1) the 100% of FUL; or (2) the 60% of AWP, with an estimated savings across 3 years of US$1614,191.
2.
As an alternative to the use of the Medi-Cal fee schedule as the primary pricing mechanism for PDDs, we suggest calculating the maximum fee as the lower of (1) 100% of NADAC, which is used for outpatient Medicaid payments in Alaska, Delaware, and Nevada; or (2) 97% of WAC (typically used to sell drugs to wholesalers and also the primary pricing used by the Wisconsin Medicaid system) [29] . Then, for those drugs not covered by either NADAC or WAC, we suggest using 60% of AWP as the secondary pricing system. Switching to a NADAC/WAC pricing benchmark would be cost saving compared with the current CAWCS pricing scheme with estimated cost savings of US$81,181,760 over the 3 years. 
Discussion
Physician-dispensed drugs in the CAWCS account for 27% of all pharmaceutical products and US$243 million in paid claims across 2011-2013. Although there was only a 6.3% relative increase in claims over this period, there was a 24.6% relative increase in the total payments and a 26.7% increase in cost/paid claims, suggesting that physicians are not dispensing more drugs, but more expensive drugs. Among different WC systems, the costs per claim was 80% higher for drugs dispensed by California's physicians compared with the 17-state median, suggesting that there may be room for offering lower payments for PDDs dispensed in the CAWCS [30] . The therapeutic class of drugs dispensed by physicians is consistent with what is expected for drug treatment of injured workers, including primarily analgesics and anti-inflammatory agents, where the percent of relative payments was lower than the percent of the relative number of PDD claims. Only for gastrointestinal drugs is the relative percent payment (29%) higher than the relative percentage of paid claims (13%), indicating that higher priced gastrointestinal drugs are a factor in the increasing total PDDs over time shown in our study.
We found that the current CAWCS pricing benchmark (Medi-Cal) provided prices for 92.7% of PDD claims during 2011-2013 and increased to 95.3% in 2013, leaving only 7.3% of PDD claims during 2011-2013 priced by AWP. Therefore, for PDDs Medi-Cal, prices should be a good selection for the primary benchmark compared with all other alternatives. However, from 2013 to 2018, the number of Medi-Cal patients moving to managed care systems has increased, resulting in an increasing loss of their Medi-Cal drug claims along with their prices. The AWP benchmark should also be considered as a primary pricing benchmark because this analysis shows that it had prices for the most (99.9%) CAWCS PDDs. However, AWP has lost favor as a [31] . In 2009, a lawsuit was filed against First DataBank who publishes AWP prices for improper inflation of AWP prices, and this led many states to look for an alternative primary pricing benchmark [32] . The CMS published a new benchmark (NADAC), created through their sponsored national survey of actual invoice prices paid by retail pharmacies to wholesalers, and many Medicaid programs (including California's Medi-Cal) are adopting NADAC as their new pricing benchmark, available as of 2012 [31, 32] . This analysis showed that NADAC prices were the second most comprehensive price system with prices for 86.12% of PDD claims. National average drug acquisition cost is based on a monthly random sample of community pharmacy paid invoices, which is calculated, reported, and overseen by the CMS and is more difficult to manipulate. Therefore, NADAC becomes the most trustworthy, timely, and comprehensive alternative primary pricing benchmark for PDD repricing in CAWCS. National average drug acquisition cost cannot be used as a secondary pricing benchmark because it provided a price for only 26.7% of claims that were not priced by Medi-Cal. The financial implication of adopting 100% NADAC as a primary pricing benchmark would be a decrease in CAWCS drug spending by 33.5%.
Wholesale acquisition cost is the list price of a drug from a manufacturer to a wholesaler but it does not reflect actual acquisition costs after rebates or discounts and had prices for only 80% of CAWCS PDDs; [14] it therefore was not further considered as a primary benchmark. Wholesale acquisition cost is more transparent than AWP but it is subject to inflation by manufacturers [33] . Wholesale acquisition cost could be used as secondary pricing benchmarks for claims that are not priced by Medi-Cal, FUL pricing was the second most comprehensive price system for claims not priced by Medi-Cal with a coverage of 54.9% of PDD claims, but the percentage decreased over the years. This finding suggests that there is an increase in prescribing brand drugs as FUL is determined by CMS only for generic drugs with multiple sources [17, 18] . The FUL could be used as a secondary pricing benchmark for PDD claims that have no Medi-Cal prices. In general, all list prices such as AWP, WAC, and DP are not subject to governmental oversight and we suggest their use only as secondary benchmarks.
Physician drug dispensing avoids the safety check of pharmacists on medication; plus physicians are allowed to bill for medication and generate revenue from this service. This could lead to suboptimal prescribing practices as physician dispensing does not have the same oversight as pharmacy dispensing. Therefore, the CAWCS has a responsibility to patients and employers in ensuring employer premiums are appropriately spent. Adoption of any new policy should warrant a follow-up study to validate findings and ensure the impact of the policy matches the original intent.
Limitations
The CAWCS data available for this study covered the years from 2011 to 2015 but we only analyzed data from 2011 to 2013 because the low number of claims in the 2 later years demonstrated that the claims were not fully resolved in these years. Most claims data (Medicare for example) are not fully processed until 6-12 months after the claim date, but the CAWCS data showed that claims were not complete until up to 2 years. As a result, our data are several years old and may not fully represent today's prices for PDDs, and this is a limitation of our analysis. We think our ability to demonstrate trends across 3 years will help mitigate this limitation, but a follow-up analysis testing our suggested repricing methods in more recent CAWCS years is desirable.
Another limitation was that NADAC prices only started to be provided in 2012, thus to estimate these prices, we deflated NADAC prices from 2012 by the 2011 annual Consumer Price Index inflation rate for prescription drugs. In addition, as NADAC prices are accumulated, it is likely that the number of prices available will increase, thus this pricing alternative may be even more useful as a primary pricing benchmark. Our analysis of PDDs excluded compounded drugs and medical foods, which are increasingly being dispensed by physicians. We made the decision to exclude these product categories because they have a very different pricing structure than the prescription drugs we included, thus we would be unable to suggest the same pricing alternative for compounded drugs or medical food. Thus, although this separation of PDDs best fit our research purpose, it is important to understand that our analysis is unable to further elucidate if our finding that PDD claims over time are relatively stable is because of shift of dispensing to favor compounded drugs and medical foods, as some studies suggest. We are currently analyzing CAWCS pricing of compounded drugs and medical foods, which will assess their cost trends to the CAWCS.
Finally, the results from this study were based on CAWCS data, thus the results may not be directly generalized to other states' workers' compensation systems as their prescribing practices may differ from what is seen in California. However, the CAWCS is the largest state workers' compensation program in USA, accounting for 11.9% of all state-covered workers and 20.6% of all states' total paid benefit in 2013; therefore, it may represent a significant proportion of all US workers' compensation claims, providing a good example for other workers' compensation systems. Despite these limitations, the analysis provided a robust picture of the impact different price schemes would have on the CAWCS.
Conclusion
This analysis allows us to consider the implications of changing from the current pricing benchmarks to alternative benchmark(s) for PDDs. To find an alternative pricing benchmark for PDDs that maximizes price availability and optimizes CAWCS healthcare resources dollars without changing the drugs dispensed, we examined different scenarios. The CAWCS current Medi-Cal pricing for PDDs is better than all alternatives, but it requires combinations of pricing benchmarks to maximize price availability, and this pricing availability may decrease over time as MediCal moves to managed care. Given the loss of confidence in AWP as a pricing benchmark and the current adoption by the CMS of NADAC pricing, we recommended using this benchmark as the best primary pricing benchmark for CAWCS for PDDs. The use of NADAC will be budget neutral and may provide savings to the CAWCS. All primary pricing benchmarks will require a choice of a secondary benchmark to price PDDs without prices in the primary option, but these combinations can provide a valid and budget-neutral pricing scheme for CAWCS PDDs.
